Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
about
Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.Thiomers: forms, functions and applications to nanomedicine.Drug nanoparticles: formulating poorly water-soluble compounds.Thiomers: promising platform for macromolecular drug delivery.Recent advancements in mechanical reduction methods: particulate systems.Drug solubility: importance and enhancement techniques.Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers.Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution.Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble DrugsNanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical StabilityNanosuspension Technologies for Delivery of Poorly Soluble Drugs
P2860
Q34733880-39086E43-B7FA-42E7-A7C2-981C7964B7CEQ36918044-D59E5308-610A-4794-82CE-092473F0583AQ37109079-EFB7834B-6861-478F-9D31-DEC74FB4688AQ38063302-6303C03E-D8ED-4911-B928-2734D109FB5BQ38132471-50924C10-A941-439B-9765-565358502940Q41885580-94942144-3DFF-4652-B700-645CE9B31BE3Q42583413-176617FA-32AE-4305-8F9A-4E6A098C5006Q43025626-C5BC02D6-A7C9-4E09-AF1D-F5C8AEC22A11Q45887220-F3B6A9A9-6811-488F-A250-143DB96FF5B8Q45998080-61422896-200C-4020-BADE-85E92A117620Q50777721-6C2C4E23-0EA3-4CD1-80DE-B02DE7E3709CQ57343790-76F99C9E-7CAD-44FB-939D-4FE9FA85A5B3Q58726467-7D049EEA-030F-47A6-809E-5F9107088F38Q59113220-CEEC0F83-8593-405B-A296-307A5C4AC311
P2860
Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Nanosuspension formulations fo ...... ronolactone as model compound.
@en
Nanosuspension formulations fo ...... ronolactone as model compound.
@nl
type
label
Nanosuspension formulations fo ...... ronolactone as model compound.
@en
Nanosuspension formulations fo ...... ronolactone as model compound.
@nl
prefLabel
Nanosuspension formulations fo ...... ronolactone as model compound.
@en
Nanosuspension formulations fo ...... ronolactone as model compound.
@nl
P2093
P2860
P356
P1476
Nanosuspension formulations fo ...... ronolactone as model compound.
@en
P2093
Langguth P
Spahn-Langguth H
Vergnault G
P2860
P304
P356
10.1081/DDC-52182
P407
P577
2005-03-01T00:00:00Z